These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 32241795

  • 1. Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial.
    Pazmino S, Boonen A, Stouten V, De Cock D, Joly J, Van der Elst K, Westhovens R, Verschueren P.
    Ann Rheum Dis; 2020 May; 79(5):556-565. PubMed ID: 32241795
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial.
    Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K, Westhovens R.
    Ann Rheum Dis; 2017 Mar; 76(3):511-520. PubMed ID: 27432356
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA.
    Stouten V, Westhovens R, Pazmino S, De Cock D, Van der Elst K, Joly J, Verschueren P, CareRA study group.
    Rheumatology (Oxford); 2019 Dec 01; 58(12):2284-2294. PubMed ID: 31236568
    [Abstract] [Full Text] [Related]

  • 4. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
    Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K, Westhovens R.
    Ann Rheum Dis; 2015 Jan 01; 74(1):27-34. PubMed ID: 25359382
    [Abstract] [Full Text] [Related]

  • 5. Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial.
    Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Van der Elst K, Meyfroidt S, Westhovens R, CareRA study group.
    Arthritis Res Ther; 2015 Apr 09; 17(1):97. PubMed ID: 25889222
    [Abstract] [Full Text] [Related]

  • 6. Short-term glucocorticoids reduce risk of chronic NSAID and analgesic use in early methotrexate-treated rheumatoid arthritis patients with favourable prognosis: subanalysis of the CareRA randomised controlled trial.
    Pazmino S, Boonen A, De Cock D, Stouten V, Joly J, Bertrand D, Westhovens R, Verschueren P.
    RMD Open; 2021 May 09; 7(2):. PubMed ID: 34031262
    [Abstract] [Full Text] [Related]

  • 7. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
    Scott DL, Ibrahim F, Farewell V, O'Keeffe AG, Ma M, Walker D, Heslin M, Patel A, Kingsley G.
    Health Technol Assess; 2014 Oct 09; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
    [Abstract] [Full Text] [Related]

  • 8. Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone.
    Korthals-de Bos I, Van Tulder M, Boers M, Verhoeven AC, Adèr HJ, Bibo J, Boonen A, Van Der Linden S.
    J Rheumatol; 2004 Sep 09; 31(9):1709-16. PubMed ID: 15338488
    [Abstract] [Full Text] [Related]

  • 9. Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial.
    Stouten V, Westhovens R, Pazmino S, De Cock D, Van der Elst K, Joly J, Bertrand D, Verschueren P.
    Ann Rheum Dis; 2021 Aug 09; 80(8):965-973. PubMed ID: 33811036
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij Reumatoïde Artritis.
    Verhoeven AC, Bibo JC, Boers M, Engel GL, van der Linden S.
    Br J Rheumatol; 1998 Oct 09; 37(10):1102-9. PubMed ID: 9825750
    [Abstract] [Full Text] [Related]

  • 11. Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry.
    Vermeer M, Kievit W, Kuper HH, Braakman-Jansen LM, Bernelot Moens HJ, Zijlstra TR, den Broeder AA, van Riel PL, Fransen J, van de Laar MA.
    BMC Musculoskelet Disord; 2013 Dec 13; 14():350. PubMed ID: 24330489
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial.
    Eriksson JK, Karlsson JA, Bratt J, Petersson IF, van Vollenhoven RF, Ernestam S, Geborek P, Neovius M.
    Ann Rheum Dis; 2015 Jun 13; 74(6):1094-101. PubMed ID: 24737786
    [Abstract] [Full Text] [Related]

  • 13. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.
    Health Technol Assess; 2006 Nov 13; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [Abstract] [Full Text] [Related]

  • 14. Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up.
    Poppelaars PBM, van Tuyl LHD, Boers M.
    Ann Rheum Dis; 2019 May 13; 78(5):586-589. PubMed ID: 30808623
    [Abstract] [Full Text] [Related]

  • 15. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C, Tzioufas A, Goules A, Kourlaba G, Theodoratou T, Christou P, Maniadakis N.
    Rheumatol Int; 2017 Sep 13; 37(9):1441-1452. PubMed ID: 28523420
    [Abstract] [Full Text] [Related]

  • 16. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective.
    Schipper LG, Kievit W, den Broeder AA, van der Laar MA, Adang EM, Fransen J, van Riel PL.
    Rheumatology (Oxford); 2011 Jul 13; 50(7):1320-30. PubMed ID: 21371999
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness of maintenance therapy with methotrexate compared with leflunomide for patients with RA having achieved disease control with both these drugs: results of a predefined sub-analysis of CareRA, a pragmatic RCT.
    Stouten V, Michiels S, Westhovens R, De Cock D, Belba A, Pazmino S, Van der Elst K, Joly J, Verschueren P.
    Clin Rheumatol; 2020 Sep 13; 39(9):2593-2601. PubMed ID: 32166429
    [Abstract] [Full Text] [Related]

  • 18. Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial.
    de Jong PH, Hazes JM, Buisman LR, Barendregt PJ, van Zeben D, van der Lubbe PA, Gerards AH, de Jager MH, de Sonnaville PB, Grillet BA, Luime JJ, Weel AE.
    Rheumatology (Oxford); 2016 Dec 13; 55(12):2138-2147. PubMed ID: 27581208
    [Abstract] [Full Text] [Related]

  • 19. Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial.
    Konijn NPC, van Tuyl LHD, Boers M, den Uyl D, Ter Wee MM, van der Wijden LKM, Bultink IEM, Kerstens PJSM, Voskuyl AE, van Schaardenburg D, Nurmohamed MT, Lems WF.
    Rheumatology (Oxford); 2017 Sep 01; 56(9):1586-1596. PubMed ID: 28859326
    [Abstract] [Full Text] [Related]

  • 20. Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial.
    Vanier A, Mariette X, Tubach F, Fautrel B, STRASS Study Group.
    Value Health; 2017 Apr 01; 20(4):577-585. PubMed ID: 28407999
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.